.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Moodys
Julphar
Dow
Teva
Fish and Richardson
Johnson and Johnson
Federal Trade Commission
US Department of Justice
Medtronic

Generated: September 20, 2017

DrugPatentWatch Database Preview

Fesoterodine fumarate - Generic Drug Details

« Back to Dashboard

What are the generic sources for fesoterodine fumarate and what is the scope of fesoterodine fumarate freedom to operate?

Fesoterodine fumarate
is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Alkem Labs Ltd, and Pfizer, and is included in three NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fesoterodine fumarate has one hundred and twenty patent family members in thirty-three countries.

There are thirteen drug master file entries for fesoterodine fumarate. Five suppliers are listed for this compound. There are nine tentative approvals for this compound.

Summary for Generic Name: fesoterodine fumarate

Tradenames:2
Patents:8
Applicants:3
NDAs:3
Drug Master File Entries: see list13
Suppliers / Packagers: see list5
Bulk Api Vendors: see list29
Clinical Trials: see list589
Patent Applications: see list15
Drug Prices:see low prices
DailyMed Link:fesoterodine fumarate at DailyMed

Tentative approvals for FESOTERODINE FUMARATE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe4MGTABLET, EXTENDED RELEASE;ORAL
► Subscribe► Subscribe8MGTABLET, EXTENDED RELEASE;ORAL
► Subscribe► Subscribe8MGTABLET, EXTENDED RELEASE;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-001Oct 31, 2008ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-001Oct 31, 2008ABRXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-001Oct 31, 2008ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008ABRXYesYes► Subscribe► Subscribe ► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-001Oct 31, 2008ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Aurobindo Pharma Ltd
FESOTERODINE FUMARATE
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL205007-002Feb 17, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fesoterodine fumarate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,364,541Pharmaceutical compositions comprising Fesoterodine► Subscribe
7,230,030Derivatives of 3,3-diphenylpropylamines► Subscribe
6,713,464 Derivatives of 3,3-diphenylpropylamines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fesoterodine fumarate

Country Document Number Estimated Expiration
Ukraine73324► Subscribe
Hungary226490► Subscribe
Israel139110► Subscribe
China1207268► Subscribe
Australia748057► Subscribe
World Intellectual Property Organization (WIPO)9958478► Subscribe
Germany19955190► Subscribe
Cyprus1110389► Subscribe
Poland202489► Subscribe
Portugal1690536► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FESOTERODINE FUMARATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2007008,C1230209Lithuania► SubscribePRODUCT NAME: FESOTERODINUM; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010 20070420
C/GB07/053United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/053 GRANTED TO SCHWARZ PHARMA AG IN RESPECT OF THE PRODUCT FESOTERODINE AND ITS SALTS WITH PHYSIOLOGICALLY ACCEPTABLE ACIDS, INCLUDING FUMARIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6299 DATED 10 FEBRUARY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 23 APRIL 2022.
365Luxembourg► Subscribe91365, EXPIRES: 20220420
C037/2007Ireland► SubscribeSPC037/2007: 20080507, EXPIRES: 20220419
C0050France► SubscribePRODUCT NAME: FESOTERODINE ET SES SELS AVEC DES ACIDES PHYSIOLOGIQUEMENT ACCEPTABLES NOTAMMENT L ACIDE FUMARIQUE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/386/001 DU 20070420; REGISTRATION NO/DATE AT EEC: EU/1/07/386/001 DU 20070420
8Finland► Subscribe
1077912/01Switzerland► SubscribePRODUCT NAME: FESOTERODIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58743 18.12.2008
2007 00046Denmark► Subscribe
2007008Lithuania► SubscribePRODUCT NAME: FESOTERODINUM; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010 20070420
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
McKesson
Covington
Johnson and Johnson
Fish and Richardson
Accenture
McKinsey
Dow
Julphar
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot